Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30

$34.33−1.76 (-4.88%)

Close on Nov 13, 2026Market cap $1.91BP/E –Yield –

Maze Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Maze Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?